Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1436108 | 0.82 | PTPN1 (0.54) | MAOBALDH1A1SCN8ATAAR1KCNH2 | |
| SCHEMBL6357114 | 0.81 | MAOB (0.49) | MAOBKIF11ALDH1A1PPARASCN8A | |
| SCHEMBL16794563 | 0.79 | MAOB (0.59) | MAOBKIF11ALDH1A1SCN8ATAAR1 | |
| SCHEMBL4414015 | 0.79 | SMN1; SMN2 (0.58) | MAOBKIF11ALDH1A1PPARASCN8A | |
| SCHEMBL14420391 | 0.79 | HRH4 (0.56) | MAOBKIF11ALDH1A1SCN8AKCNH2 | |
| SCHEMBL27900254 | 0.78 | MAOB (0.57) | MAOBKIF11TAAR1IDO1 | |
| SCHEMBL14021244 | 0.77 | HRH4 (0.50) | MAOBKIF11ALDH1A1PPARASCN8A | |
| SCHEMBL2092499 | 0.77 | KIF11 (0.57) | MAOBKIF11ALDH1A1PPARATAAR1 | |
| Tert-Butylamine SCHEMBL5960929 | 0.76 | MAOB (0.47) | MAOBKIF11ALDH1A1PPARASCN8A | |
| SCHEMBL3542893 | 0.75 | SCN8A (0.47) | MAOBKIF11ALDH1A1PPARASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266841-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-20150045375-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-02-12 | — | — | US | disclosed |
| EP-1292611-B1 | GLYCOPEPTIDE CARBOXY-SACCHARIDE DERIVATIVES | THERAVANCE INC (US) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045375-A1 | NOVEL COMPOUNDS | PLA2G7, ALOX15B, PLA2G1B | MAOB 445/4885KIF11 4841/4885ALDH1A1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.